MENU
JDOC
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

JDOC stock forecast, quote, news & analysis

The investment seeks to provide long-term capital appreciation... Show more

Category: #Health
JDOC
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for JDOC with price predictions
Jul 31, 2026

JDOC sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for JDOC moved above the 200-day moving average on July 08, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on JDOC as a result. In of 43 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JDOC advanced for three days, in of 104 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 144 cases where JDOC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for JDOC moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 34 cases where JDOC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for JDOC turned negative on July 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JDOC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JDOC broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), CVS HEALTH Corp (NYSE:CVS), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks to provide long-term capital appreciation. The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.

Market Cap

The average market capitalization across the JPMorgan Healthcare Leaders ETF ETF is 97.57B. The market cap for tickers in the group ranges from 1.57B to 1.02T. LLY holds the highest valuation in this group at 1.02T. The lowest valued company is SRPT at 1.57B.

High and low price notable news

The average weekly price growth across all stocks in the JPMorgan Healthcare Leaders ETF ETF was -0%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was 4%. REGN experienced the highest price growth at 16%, while AGIO experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the JPMorgan Healthcare Leaders ETF ETF was 15%. For the same stocks of the ETF, the average monthly volume growth was -5% and the average quarterly volume growth was -18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 43
SMR Rating: 62
Profit Risk Rating: 69
Seasonality Score: -14 (-100 ... +100)
View a ticker or compare two or three
JDOC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
J.P. Morgan Exchange-Traded Fund Trust390 Madison AvenueNew York
Phone
(844) 457-6383
Web
jpmorganfunds.com
JDOC sees its 50-day moving average cross bullishly above its 200-day moving average